aluates Reports

$ 0.0

Automative

Irritable Bowel Syndrome (IBS)- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Published Date: August 2025

Report Code: QYRE-Auto-37T9015

Global Irritable Bowel Syndrome IBS Market Size Status and Forecast 2022

BUY CHAPTERS

Irritable Bowel Syndrome (IBS)- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Code: QYRE-Auto-37T9015

Report

August 2025

Pages:91

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Takeda

Sucampo Pharmaceuticals (Mallinckrodt)

Sebela Pharmaceuticals Inc

Astellas Pharmaceuticals

Allergan plc

Bausch Health

Irritable Bowel Syndrome (IBS)- Market Size

The global market for Irritable Bowel Syndrome (IBS) was estimated to be worth US$ 6252 million in 2024 and is forecast to a readjusted size of US$ 16410 million by 2031 with a CAGR of 15.0% during the forecast period 2025-2031.

Irritable Bowel Syndrome (IBS)- Market

Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled international IBS prevalence rate of about 11.2%.

North America is the largest region of Irritable Bowel Syndrome (IBS), with a market share about 75%. Allergan, Valeant Pharmaceuticals, Takeda, Sucampo Pharmaceuticals and McNeil Consumer Healthcare are the top 5 manufacturers of industry, and they had about 80% combined market share.

This report aims to provide a comprehensive presentation of the global market for Irritable Bowel Syndrome (IBS), focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Irritable Bowel Syndrome (IBS) by region & country, by Type, and by Application.

The Irritable Bowel Syndrome (IBS) market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Irritable Bowel Syndrome (IBS).

Market Segmentation

Scope of Irritable Bowel Syndrome (IBS)- Market Report

Report Metric	Details
Report Name	Irritable Bowel Syndrome (IBS)- Market
Forecasted market size in 2031	US$ 16410 million
CAGR	15.0%
Forecasted years	2025 - 2031
Segment by Type	IBS-D Drug IBS-C Drug Others
Segment by Application	Women Men
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Bausch Health, Allergan, Takeda, Sucampo Pharmaceuticals (Mallinckrodt), Sebela Pharmaceuticals Inc, Astellas Pharmaceuticals
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Irritable Bowel Syndrome (IBS) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Irritable Bowel Syndrome (IBS) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Irritable Bowel Syndrome (IBS) in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Irritable Bowel Syndrome (IBS)- Market size in 2031?

Ans: The Irritable Bowel Syndrome (IBS)- Market size in 2031 will be US$ 16410 million.

What is the Irritable Bowel Syndrome (IBS)- Market share by region?

Ans: North America is the largest region of Irritable Bowel Syndrome (IBS), with a market share about 75%.

What is the market share of major companies in Irritable Bowel Syndrome (IBS)- Market?

Ans: Allergan, Valeant Pharmaceuticals, Takeda, Sucampo Pharmaceuticals and McNeil Consumer Healthcare are the top 5 manufacturers of industry, and they had about 80% combined market share.

Who are the main players in the Irritable Bowel Syndrome (IBS)- Market report?

Ans: The main players in the Irritable Bowel Syndrome (IBS)- Market are Bausch Health, Allergan, Takeda, Sucampo Pharmaceuticals (Mallinckrodt), Sebela Pharmaceuticals Inc, Astellas Pharmaceuticals

What are the Application segmentation covered in the Irritable Bowel Syndrome (IBS)- Market report?

Ans: The Applications covered in the Irritable Bowel Syndrome (IBS)- Market report are Women, Men

What are the Type segmentation covered in the Irritable Bowel Syndrome (IBS)- Market report?

Ans: The Types covered in the Irritable Bowel Syndrome (IBS)- Market report are IBS-D Drug, IBS-C Drug, Others

Recommended Reports

Bowel Disease Therapeutics

Digestive Health Devices

Functional GI Drugs

1 Market Overview

1.1 Irritable Bowel Syndrome (IBS) Product Introduction

1.2 Global Irritable Bowel Syndrome (IBS) Market Size Forecast (2020-2031)

1.3 Irritable Bowel Syndrome (IBS) Market Trends & Drivers

1.3.1 Irritable Bowel Syndrome (IBS) Industry Trends

1.3.2 Irritable Bowel Syndrome (IBS) Market Drivers & Opportunity

1.3.3 Irritable Bowel Syndrome (IBS) Market Challenges

1.3.4 Irritable Bowel Syndrome (IBS) Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Irritable Bowel Syndrome (IBS) Players Revenue Ranking (2024)

2.2 Global Irritable Bowel Syndrome (IBS) Revenue by Company (2020-2025)

2.3 Key Companies Irritable Bowel Syndrome (IBS) Manufacturing Base Distribution and Headquarters

2.4 Key Companies Irritable Bowel Syndrome (IBS) Product Offered

2.5 Key Companies Time to Begin Mass Production of Irritable Bowel Syndrome (IBS)

2.6 Irritable Bowel Syndrome (IBS) Market Competitive Analysis

2.6.1 Irritable Bowel Syndrome (IBS) Market Concentration Rate (2020-2025)

2.6.2 Global 5 and 10 Largest Companies by Irritable Bowel Syndrome (IBS) Revenue in 2024

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Irritable Bowel Syndrome (IBS) as of 2024)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 IBS-D Drug

3.1.2 IBS-C Drug

3.1.3 Others

3.2 Global Irritable Bowel Syndrome (IBS) Sales Value by Type

3.2.1 Global Irritable Bowel Syndrome (IBS) Sales Value by Type (2020 VS 2024 VS 2031)

3.2.2 Global Irritable Bowel Syndrome (IBS) Sales Value, by Type (2020-2031)

3.2.3 Global Irritable Bowel Syndrome (IBS) Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Women

4.1.2 Men

4.2 Global Irritable Bowel Syndrome (IBS) Sales Value by Application

4.2.1 Global Irritable Bowel Syndrome (IBS) Sales Value by Application (2020 VS 2024 VS 2031)

4.2.2 Global Irritable Bowel Syndrome (IBS) Sales Value, by Application (2020-2031)

4.2.3 Global Irritable Bowel Syndrome (IBS) Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

5.1 Global Irritable Bowel Syndrome (IBS) Sales Value by Region

5.1.1 Global Irritable Bowel Syndrome (IBS) Sales Value by Region: 2020 VS 2024 VS 2031

5.1.2 Global Irritable Bowel Syndrome (IBS) Sales Value by Region (2020-2025)

5.1.3 Global Irritable Bowel Syndrome (IBS) Sales Value by Region (2026-2031)

5.1.4 Global Irritable Bowel Syndrome (IBS) Sales Value by Region (%), (2020-2031)

5.2 North America

5.2.1 North America Irritable Bowel Syndrome (IBS) Sales Value, 2020-2031

5.2.2 North America Irritable Bowel Syndrome (IBS) Sales Value by Country (%), 2024 VS 2031

5.3 Europe

5.3.1 Europe Irritable Bowel Syndrome (IBS) Sales Value, 2020-2031

5.3.2 Europe Irritable Bowel Syndrome (IBS) Sales Value by Country (%), 2024 VS 2031

5.4 Asia Pacific

5.4.1 Asia Pacific Irritable Bowel Syndrome (IBS) Sales Value, 2020-2031

5.4.2 Asia Pacific Irritable Bowel Syndrome (IBS) Sales Value by Region (%), 2024 VS 2031

5.5 South America

5.5.1 South America Irritable Bowel Syndrome (IBS) Sales Value, 2020-2031

5.5.2 South America Irritable Bowel Syndrome (IBS) Sales Value by Country (%), 2024 VS 2031

5.6 Middle East & Africa

5.6.1 Middle East & Africa Irritable Bowel Syndrome (IBS) Sales Value, 2020-2031

5.6.2 Middle East & Africa Irritable Bowel Syndrome (IBS) Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Irritable Bowel Syndrome (IBS) Sales Value Growth Trends, 2020 VS 2024 VS 2031

6.2 Key Countries/Regions Irritable Bowel Syndrome (IBS) Sales Value, 2020-2031

6.3 United States

6.3.1 United States Irritable Bowel Syndrome (IBS) Sales Value, 2020-2031

6.3.2 United States Irritable Bowel Syndrome (IBS) Sales Value by Type (%), 2024 VS 2031

6.3.3 United States Irritable Bowel Syndrome (IBS) Sales Value by Application, 2024 VS 2031

6.4 Europe

6.4.1 Europe Irritable Bowel Syndrome (IBS) Sales Value, 2020-2031

6.4.2 Europe Irritable Bowel Syndrome (IBS) Sales Value by Type (%), 2024 VS 2031

6.4.3 Europe Irritable Bowel Syndrome (IBS) Sales Value by Application, 2024 VS 2031

6.5 China

6.5.1 China Irritable Bowel Syndrome (IBS) Sales Value, 2020-2031

6.5.2 China Irritable Bowel Syndrome (IBS) Sales Value by Type (%), 2024 VS 2031

6.5.3 China Irritable Bowel Syndrome (IBS) Sales Value by Application, 2024 VS 2031

6.6 Japan

6.6.1 Japan Irritable Bowel Syndrome (IBS) Sales Value, 2020-2031

6.6.2 Japan Irritable Bowel Syndrome (IBS) Sales Value by Type (%), 2024 VS 2031

6.6.3 Japan Irritable Bowel Syndrome (IBS) Sales Value by Application, 2024 VS 2031

6.7 South Korea

6.7.1 South Korea Irritable Bowel Syndrome (IBS) Sales Value, 2020-2031

6.7.2 South Korea Irritable Bowel Syndrome (IBS) Sales Value by Type (%), 2024 VS 2031

6.7.3 South Korea Irritable Bowel Syndrome (IBS) Sales Value by Application, 2024 VS 2031

6.8 Southeast Asia

6.8.1 Southeast Asia Irritable Bowel Syndrome (IBS) Sales Value, 2020-2031

6.8.2 Southeast Asia Irritable Bowel Syndrome (IBS) Sales Value by Type (%), 2024 VS 2031

6.8.3 Southeast Asia Irritable Bowel Syndrome (IBS) Sales Value by Application, 2024 VS 2031

6.9 India

6.9.1 India Irritable Bowel Syndrome (IBS) Sales Value, 2020-2031

6.9.2 India Irritable Bowel Syndrome (IBS) Sales Value by Type (%), 2024 VS 2031

6.9.3 India Irritable Bowel Syndrome (IBS) Sales Value by Application, 2024 VS 2031

7 Company Profiles

7.1 Bausch Health

7.1.1 Bausch Health Profile

7.1.2 Bausch Health Main Business

7.1.3 Bausch Health Irritable Bowel Syndrome (IBS) Products, Services and Solutions

7.1.4 Bausch Health Irritable Bowel Syndrome (IBS) Revenue (US$ Million) & (2020-2025)

7.1.5 Bausch Health Recent Developments

7.2 Allergan

7.2.1 Allergan Profile

7.2.2 Allergan Main Business

7.2.3 Allergan Irritable Bowel Syndrome (IBS) Products, Services and Solutions

7.2.4 Allergan Irritable Bowel Syndrome (IBS) Revenue (US$ Million) & (2020-2025)

7.2.5 Allergan Recent Developments

7.3 Takeda

7.3.1 Takeda Profile

7.3.2 Takeda Main Business

7.3.3 Takeda Irritable Bowel Syndrome (IBS) Products, Services and Solutions

7.3.4 Takeda Irritable Bowel Syndrome (IBS) Revenue (US$ Million) & (2020-2025)

7.3.5 Takeda Recent Developments

7.4 Sucampo Pharmaceuticals (Mallinckrodt)

7.4.1 Sucampo Pharmaceuticals (Mallinckrodt) Profile

7.4.2 Sucampo Pharmaceuticals (Mallinckrodt) Main Business

7.4.3 Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Products, Services and Solutions

7.4.4 Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Revenue (US$ Million) & (2020-2025)

7.4.5 Sucampo Pharmaceuticals (Mallinckrodt) Recent Developments

7.5 Sebela Pharmaceuticals Inc

7.5.1 Sebela Pharmaceuticals Inc Profile

7.5.2 Sebela Pharmaceuticals Inc Main Business

7.5.3 Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Products, Services and Solutions

7.5.4 Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Revenue (US$ Million) & (2020-2025)

7.5.5 Sebela Pharmaceuticals Inc Recent Developments

7.6 Astellas Pharmaceuticals

7.6.1 Astellas Pharmaceuticals Profile

7.6.2 Astellas Pharmaceuticals Main Business

7.6.3 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Products, Services and Solutions

7.6.4 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Revenue (US$ Million) & (2020-2025)

7.6.5 Astellas Pharmaceuticals Recent Developments

8 Industry Chain Analysis

8.1 Irritable Bowel Syndrome (IBS) Industrial Chain

8.2 Irritable Bowel Syndrome (IBS) Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Irritable Bowel Syndrome (IBS) Sales Model

8.5.2 Sales Channel

8.5.3 Irritable Bowel Syndrome (IBS) Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.1.1 Research Programs/Design

10.1.1.2 Market Size Estimation

10.1.1.3 Market Breakdown and Data Triangulation

10.1.2 Data Source

10.1.2.1 Secondary Sources

10.1.2.2 Primary Sources

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Takeda

Sucampo Pharmaceuticals (Mallinckrodt)

Sebela Pharmaceuticals Inc

Astellas Pharmaceuticals

Allergan plc

Bausch Health

List of Tables

Table 1. Irritable Bowel Syndrome (IBS) Market Trends

Table 2. Irritable Bowel Syndrome (IBS) Market Drivers & Opportunity

Table 3. Irritable Bowel Syndrome (IBS) Market Challenges

Table 4. Irritable Bowel Syndrome (IBS) Market Restraints

Table 5. Global Irritable Bowel Syndrome (IBS) Revenue by Company (2020-2025) & (US$ Million)

Table 6. Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Company (2020-2025)

Table 7. Key Companies Irritable Bowel Syndrome (IBS) Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Irritable Bowel Syndrome (IBS) Product Type

Table 9. Key Companies Time to Begin Mass Production of Irritable Bowel Syndrome (IBS)

Table 10. Global Irritable Bowel Syndrome (IBS) Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Irritable Bowel Syndrome (IBS) as of 2024)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Irritable Bowel Syndrome (IBS) Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)

Table 14. Global Irritable Bowel Syndrome (IBS) Sales Value by Type (2020-2025) & (US$ Million)

Table 15. Global Irritable Bowel Syndrome (IBS) Sales Value by Type (2026-2031) & (US$ Million)

Table 16. Global Irritable Bowel Syndrome (IBS) Sales Market Share in Value by Type (2020-2025)

Table 17. Global Irritable Bowel Syndrome (IBS) Sales Market Share in Value by Type (2026-2031)

Table 18. Global Irritable Bowel Syndrome (IBS) Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)

Table 19. Global Irritable Bowel Syndrome (IBS) Sales Value by Application (2020-2025) & (US$ Million)

Table 20. Global Irritable Bowel Syndrome (IBS) Sales Value by Application (2026-2031) & (US$ Million)

Table 21. Global Irritable Bowel Syndrome (IBS) Sales Market Share in Value by Application (2020-2025)

Table 22. Global Irritable Bowel Syndrome (IBS) Sales Market Share in Value by Application (2026-2031)

Table 23. Global Irritable Bowel Syndrome (IBS) Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)

Table 24. Global Irritable Bowel Syndrome (IBS) Sales Value by Region (2020-2025) & (US$ Million)

Table 25. Global Irritable Bowel Syndrome (IBS) Sales Value by Region (2026-2031) & (US$ Million)

Table 26. Global Irritable Bowel Syndrome (IBS) Sales Value by Region (2020-2025) & (%)

Table 27. Global Irritable Bowel Syndrome (IBS) Sales Value by Region (2026-2031) & (%)

Table 28. Key Countries/Regions Irritable Bowel Syndrome (IBS) Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031

Table 29. Key Countries/Regions Irritable Bowel Syndrome (IBS) Sales Value, (2020-2025) & (US$ Million)

Table 30. Key Countries/Regions Irritable Bowel Syndrome (IBS) Sales Value, (2026-2031) & (US$ Million)

Table 31. Bausch Health Basic Information List

Table 32. Bausch Health Description and Business Overview

Table 33. Bausch Health Irritable Bowel Syndrome (IBS) Products, Services and Solutions

Table 34. Revenue (US$ Million) in Irritable Bowel Syndrome (IBS) Business of Bausch Health (2020-2025)

Table 35. Bausch Health Recent Developments

Table 36. Allergan Basic Information List

Table 37. Allergan Description and Business Overview

Table 38. Allergan Irritable Bowel Syndrome (IBS) Products, Services and Solutions

Table 39. Revenue (US$ Million) in Irritable Bowel Syndrome (IBS) Business of Allergan (2020-2025)

Table 40. Allergan Recent Developments

Table 41. Takeda Basic Information List

Table 42. Takeda Description and Business Overview

Table 43. Takeda Irritable Bowel Syndrome (IBS) Products, Services and Solutions

Table 44. Revenue (US$ Million) in Irritable Bowel Syndrome (IBS) Business of Takeda (2020-2025)

Table 45. Takeda Recent Developments

Table 46. Sucampo Pharmaceuticals (Mallinckrodt) Basic Information List

Table 47. Sucampo Pharmaceuticals (Mallinckrodt) Description and Business Overview

Table 48. Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Products, Services and Solutions

Table 49. Revenue (US$ Million) in Irritable Bowel Syndrome (IBS) Business of Sucampo Pharmaceuticals (Mallinckrodt) (2020-2025)

Table 50. Sucampo Pharmaceuticals (Mallinckrodt) Recent Developments

Table 51. Sebela Pharmaceuticals Inc Basic Information List

Table 52. Sebela Pharmaceuticals Inc Description and Business Overview

Table 53. Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Products, Services and Solutions

Table 54. Revenue (US$ Million) in Irritable Bowel Syndrome (IBS) Business of Sebela Pharmaceuticals Inc (2020-2025)

Table 55. Sebela Pharmaceuticals Inc Recent Developments

Table 56. Astellas Pharmaceuticals Basic Information List

Table 57. Astellas Pharmaceuticals Description and Business Overview

Table 58. Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Products, Services and Solutions

Table 59. Revenue (US$ Million) in Irritable Bowel Syndrome (IBS) Business of Astellas Pharmaceuticals (2020-2025)

Table 60. Astellas Pharmaceuticals Recent Developments

Table 61. Key Raw Materials Lists

Table 62. Raw Materials Key Suppliers Lists

Table 63. Irritable Bowel Syndrome (IBS) Downstream Customers

Table 64. Irritable Bowel Syndrome (IBS) Distributors List

Table 65. Research Programs/Design for This Report

Table 66. Key Data Information from Secondary Sources

Table 67. Key Data Information from Primary Sources

Table 68. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Irritable Bowel Syndrome (IBS) Product Picture

Figure 2. Global Irritable Bowel Syndrome (IBS) Sales Value, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Global Irritable Bowel Syndrome (IBS) Sales Value (2020-2031) & (US$ Million)

Figure 4. Irritable Bowel Syndrome (IBS) Report Years Considered

Figure 5. Global Irritable Bowel Syndrome (IBS) Players Revenue Ranking (2024) & (US$ Million)

Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Irritable Bowel Syndrome (IBS) Revenue in 2024

Figure 7. Irritable Bowel Syndrome (IBS) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 8. IBS-D Drug Picture

Figure 9. IBS-C Drug Picture

Figure 10. Others Picture

Figure 11. Global Irritable Bowel Syndrome (IBS) Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)

Figure 12. Global Irritable Bowel Syndrome (IBS) Sales Value Market Share by Type, 2024 & 2031

Figure 13. Product Picture of Women

Figure 14. Product Picture of Men

Figure 15. Global Irritable Bowel Syndrome (IBS) Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)

Figure 16. Global Irritable Bowel Syndrome (IBS) Sales Value Market Share by Application, 2024 & 2031

Figure 17. North America Irritable Bowel Syndrome (IBS) Sales Value (2020-2031) & (US$ Million)

Figure 18. North America Irritable Bowel Syndrome (IBS) Sales Value by Country (%), 2024 VS 2031

Figure 19. Europe Irritable Bowel Syndrome (IBS) Sales Value, (2020-2031) & (US$ Million)

Figure 20. Europe Irritable Bowel Syndrome (IBS) Sales Value by Country (%), 2024 VS 2031

Figure 21. Asia Pacific Irritable Bowel Syndrome (IBS) Sales Value, (2020-2031) & (US$ Million)

Figure 22. Asia Pacific Irritable Bowel Syndrome (IBS) Sales Value by Region (%), 2024 VS 2031

Figure 23. South America Irritable Bowel Syndrome (IBS) Sales Value, (2020-2031) & (US$ Million)

Figure 24. South America Irritable Bowel Syndrome (IBS) Sales Value by Country (%), 2024 VS 2031

Figure 25. Middle East & Africa Irritable Bowel Syndrome (IBS) Sales Value, (2020-2031) & (US$ Million)

Figure 26. Middle East & Africa Irritable Bowel Syndrome (IBS) Sales Value by Country (%), 2024 VS 2031

Figure 27. Key Countries/Regions Irritable Bowel Syndrome (IBS) Sales Value (%), (2020-2031)

Figure 28. United States Irritable Bowel Syndrome (IBS) Sales Value, (2020-2031) & (US$ Million)

Figure 29. United States Irritable Bowel Syndrome (IBS) Sales Value by Type (%), 2024 VS 2031

Figure 30. United States Irritable Bowel Syndrome (IBS) Sales Value by Application (%), 2024 VS 2031

Figure 31. Europe Irritable Bowel Syndrome (IBS) Sales Value, (2020-2031) & (US$ Million)

Figure 32. Europe Irritable Bowel Syndrome (IBS) Sales Value by Type (%), 2024 VS 2031

Figure 33. Europe Irritable Bowel Syndrome (IBS) Sales Value by Application (%), 2024 VS 2031

Figure 34. China Irritable Bowel Syndrome (IBS) Sales Value, (2020-2031) & (US$ Million)

Figure 35. China Irritable Bowel Syndrome (IBS) Sales Value by Type (%), 2024 VS 2031

Figure 36. China Irritable Bowel Syndrome (IBS) Sales Value by Application (%), 2024 VS 2031

Figure 37. Japan Irritable Bowel Syndrome (IBS) Sales Value, (2020-2031) & (US$ Million)

Figure 38. Japan Irritable Bowel Syndrome (IBS) Sales Value by Type (%), 2024 VS 2031

Figure 39. Japan Irritable Bowel Syndrome (IBS) Sales Value by Application (%), 2024 VS 2031

Figure 40. South Korea Irritable Bowel Syndrome (IBS) Sales Value, (2020-2031) & (US$ Million)

Figure 41. South Korea Irritable Bowel Syndrome (IBS) Sales Value by Type (%), 2024 VS 2031

Figure 42. South Korea Irritable Bowel Syndrome (IBS) Sales Value by Application (%), 2024 VS 2031

Figure 43. Southeast Asia Irritable Bowel Syndrome (IBS) Sales Value, (2020-2031) & (US$ Million)

Figure 44. Southeast Asia Irritable Bowel Syndrome (IBS) Sales Value by Type (%), 2024 VS 2031

Figure 45. Southeast Asia Irritable Bowel Syndrome (IBS) Sales Value by Application (%), 2024 VS 2031

Figure 46. India Irritable Bowel Syndrome (IBS) Sales Value, (2020-2031) & (US$ Million)

Figure 47. India Irritable Bowel Syndrome (IBS) Sales Value by Type (%), 2024 VS 2031

Figure 48. India Irritable Bowel Syndrome (IBS) Sales Value by Application (%), 2024 VS 2031

Figure 49. Irritable Bowel Syndrome (IBS) Industrial Chain

Figure 50. Irritable Bowel Syndrome (IBS) Manufacturing Cost Structure

Figure 51. Channels of Distribution (Direct Sales, and Distribution)

Figure 52. Bottom-up and Top-down Approaches for This Report

Figure 53. Data Triangulation

Figure 54. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Irritable Bowel Syndrome IBS Diagnostics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Irritable Bowel Syndrome Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Irritable Bowel Syndrome Treatment Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Irritable Bowel Syndrome with Diarrhea IBS D Drugs Market Size Manufacturers Supply Chain Sales Channel and Clients 2024 2030

Global Irritable Bowel Syndrome Drug Market Research Report 2024

Global Gastrointestinal Sales Market Report Competitive Analysis and Regional Opportunities 2025 2031

Global Irritable Bowel Syndrome Medication Market Research Report 2025

Global Digestive Drugs Market Insights Forecast to 2030

Global IBS Probiotic Supplement Market Research Report 2024

Global IBS C Drugs Market Research Report 2024

Global Irritable Bowel Syndrome with Constipation Drugs Market Research Report 2024

Gastrointestinal Disorder Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Chronic Idiopathic Constipation Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Short Bowel Syndrome SBS Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Digestive Distress Treatment Market Research Report 2024

Global Gastrointestinal Therapeutics Market Research Report 2024

Global Gastrointestinal Drugs Market Research Report 2025

Global IBS Implant Market Research Report 2024

Global Healthcare Bowel Management Systems Market Insights Forecast to 2030

RELATED REPORTS

Global Insulin Coolers Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-19Z7671

Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Ossicular Prostheses Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-10V14317

Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Defibrillator Accessories Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-10O5919

Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Septicemia Diagnostic Testing Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-4I19963

Thu Sep 18 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions